CD274 and neoplasm: Suboptimal SNS-032 dosing given prior to anti-PD-L1 antibody in tumor-bearing mice engrafted with human immune cells led to the restriction of tumor growth compared with avelumab without prior SNS-032 priming or SNS-032 alone.